REPRODUKTIV YOSHDAGI AYOLLARDA TUXUMDONLAR POLIKISTOZ SINDROMI (PKS) FONIDA METABOLIK KASALLIKLAR VA INSULIN REZISTENTLIGINI PATOGENETIK DAVOLASHDA INOZITOL IZOMERLARINING GORMONAL PROFILGA TAʼSIRINI BAHOLASH.

Authors

  • Boyquvvatova Xulkar Axmedovna Samarqand Davlat Tibbiyot instituti

Keywords:

Tuxumdonlar polikistoz sindromi (PKS), miyo-inozitol, D-xiro-inositol, insulin rezistentligi, gormonal profil, testosteron, HOMA-IR, metabolik sindrom.

Abstract

Reproduktiv yoshdagi ayollarda tuxumdonlar polikistoz sindromi (PKS) bepushtlik va endokrin disfunksiyalarning asosiy sabablaridan biri hisoblanadi. Mazkur ilmiy tezisda PKS fonida rivojlanadigan metabolik kasalliklar va insulin rezistentligini patogenetik davolashda inozitol izomerlarining (miyo-inozitol va D-xiro-inozitol) gormonal profilga taʼsiri tizimli tahlil qilingan. Klinik tadqiqotlar va meta-analizlar tahlili shuni koʻrsatadiki, inozitol izomerlarining maqbul nisbatda (40:1) qoʻllanilishi qon zardobidagi erkin va umumiy testosteron, lyuteinlovchi gormon (LH) miqdorini sezilarli darajada kamaytiradi, jinsiy gormonlarni bogʻlovchi globulin (SHBG) miqdorini esa oshiradi. Shuningdek, uglevod almashinuvi koʻrsatkichlari (HOMA-IR va och qoringa insulin) barqarorlashishi isbotlangan. Inozitol patogenetik davolashda samarali va xavfsiz bioaktiv modda sifatida tavsiya etiladi.

References

1.Fitz V., Graca S., Mahalingaiah S., Liu J., Lai L. et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 2024, Vol. 109, No. 6, pp. 1630–1635.

2.Genazzani A.D., Unfer V. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria. Gynecological and Obstetric Investigation, 2024, Vol. 89, No. 2, pp. 131–139.

3.PubMed Central. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. PMC Journal of Endocrinology, 2026, Vol. 14, No. 3, pp. 1–5.

4.Kuznetsova I.V., Uspenskaya Y.B. Results of treatment with myo-Inositol and D-chiro inositol combination in ratio 5:1 in women with polycystic ovary syndrome. Gynecology, 2020, Vol. 22, No. 6, pp. 84–88.

5.Jakimiuk A.J., Szamatowicz J. Metabolic and hormonal effects of a combined Myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekologia Polska, 2019, Vol. 90, No. 1, pp. 7–10.

6.Laganà A.S., Facchinetti F. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future. Expert Opinion on Investigational Drugs, 2024, Vol. 33, No. 1, pp. 23–29.

7.Nordio M., Proietti E. The combined therapy with myo-inositol and D-chiro-inositol achieves a better clinical outcome in PCOS patients. European Review for Medical and Pharmacological Sciences, 2012, Vol. 16, No. 5, pp. 575–581.

8.Unfer V., Facchinetti F., Orrù B., Grandi G., Nestler J.E. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 2017, Vol. 6, No. 8, pp. 647–658.

9.Nestler J.E., Jakubowicz D.J., Reamer P., Gunn R.D., Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine, 1999, Vol. 340, No. 17, pp. 1314–1320.

10.Pundir J., Psaroudakis D., Savnur P., Bhide P., Sabatini L. et al. Inositol effects on reproductive outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology, 2018, Vol. 125, No. 3, pp. 299–308.

11.Minozzi M., Nordio M., d'Anna R. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences, 2019, Vol. 23, No. 12, pp. 5512–5521.

12.Facchinetti F., Orrù B., Grandi G., Unfer V. Short-term effects of myo-inositol, alpha-lactalbumin and folic acid in polycystic ovary syndrome patients. Gynecological Endocrinology, 2019, Vol. 35, No. 12, pp. 1065–1069.

Downloads

Published

2026-06-18

Conference Proceedings Volume

Section

Articles

Similar Articles

1 2 3 4 5 6 7 > >> 

You may also start an advanced similarity search for this article.